Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Multicenter, Single Dose Gene Transfer Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Subjects in the United States

NCT06747273 is registered in ClinicalTrials.gov with Sarepta Therapeutics, Inc. as lead sponsor.

NCT NCT06747273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06747273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Multicenter, Single Dose Gene Transfer Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Subjects in the United States
Lead sponsor
Sarepta Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
January 9, 2025
Completion date
June 18, 2025
Enrollment
4 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

limb girdle muscular dystrophy, limb girdle muscular dystrophy type 2d/r3